Citations

Clear

4207 citation(s) found for "Chen, Yu".

Phase I/II Trial and Pharmacokinetic Study of Cixutumumab in Pediatric Patients With Refractory Solid Tumors and Ewing Sarcoma: A Report From the Children's Oncology Group
Malempati, Suman , Weigel, Brenda J. , Ingle, Ashish M., Ahern, Charlotte H., Carroll, Julie M. , Roberts, Charles T. , Schmechel, Stephen C. , Voss, Stephan D. , Cho, Steven Y., Chen, Helen X., Krailo, Mark , Adamson, Peter C. , Blaney, Susan M. , Reid, Joel M.

Mayo Clinic

Journal of Clinical Oncology | December 19, 2011 | Volume: 30 | Issue: 3 | Pages: 256-262

10.1200/jco.2011.37.4355 | PMID 22184397 Get It

Purpose A phase I/II study of cixutumumab (IMC-A12) in children with refractory solid tumors was conducted. This study was designed to assess the toxicities, pharmacokinetics, and pharmacodynamics of cixutumumab in children to determine a recommended phase II dose and to assess antitumor activity in Ewing sarcoma (ES). Patients and Methods Pediatric patients with relapsed or refractory solid tumors were treated with cixutumumab as a 1-hour intravenous infusion once per week. Two dose levels—6 and 9 mg/kg—were evaluated using a standard three-plus-three cohort design. Patients with refractory ES were treated in an expanded phase II cohort at each dose level. Results Forty-seven eligible patients with a median age of 15 years (range, 4 to 28 years) were enrolled. Twelve patients were treated in the dose-finding phase. Hematologic and nonhematologic toxicities were generally mild and infrequent. Dose-limiting toxicities included grade 4 thrombocytopenia at 6 mg/kg and grade 3 dehydration at 9 mg/kg. Mean trough concentration (± standard deviation) at 9 mg/kg was 106 ± 57 μg/mL, which exceeded the effective trough concentration of 60 μg/mL observed in xenograft models. Three patients with ES had confirmed partial responses: one of 10 at 6 mg/kg and two of 20 at 9 mg/kg. Serum insulin-like growth factor I (IGF-I) levels consistently increased after one dose of cixutumumab. Tumor IGF-I receptor expression by immunohistochemistry did not correlate with response in patients with ES. Conclusion Cixutumumab is well tolerated in children with refractory solid tumors. The recommended phase II dose is 9 mg/kg. Limited single-agent activity of cixutumumab was seen in ES.
Next generation analytic tools for large scale genetic epidemiology studies of complex diseases
Mechanic, Leah E. , Chen, Huann‐Sheng , Chatterjee, Nilanjan , Cox, Nancy J. , Divi, Rao L., Fan, Ruzong , Harris, Emily , McAllister, Kimberly A. , Moore, Jason H. , Paltoo, Dina N., Province, Michael A. , Ramos, Erin M. , Ritchie, Marylyn D. , Roeder, Kathryn , Schaid, Daniel J. , Thomas, Duncan C. , Weinberg, Clarice R. , Witte, John S. , Zhang, Shunpu, Zöllner, Sebastian , Feuer, Eric J. , Gillanders, Elizabeth M. , Amos, Christopher I. , Jacobs, Kevin B. , Kraft, Peter , Leal, Suzanne M. , Stephens, Matthew , Weinberg, Clarice R , Province, Mike

Mayo Clinic

Genetic Epidemiology | December 6, 2011 | Volume: 36 | Issue: 1 | Pages: 22-35

10.1002/gepi.20652 | PMID 22147673 Get It

AbstractOver the past several years, genome‐wide association studies (GWAS) have succeeded in identifying hundreds of genetic markers associated with common diseases. However, most of these markers confer relatively small increments of risk and explain only a small proportion of familial clustering. To identify obstacles to future progress in genetic epidemiology research and provide recommendations to NIH for overcoming these barriers, the National Cancer Institute sponsored a workshop entitled “Next Generation Analytic Tools for Large‐Scale Genetic Epidemiology Studies of Complex Diseases” on September 15–16, 2010. The goal of the workshop was to facilitate discussions on (1) statistical strategies and methods to efficiently identify genetic and environmental factors contributing to the risk of complex disease; and (2) how to develop, apply, and evaluate these strategies for the design, analysis, and interpretation of large‐scale complex disease association studies in order to guide NIH in setting the future agenda in this area of research. The workshop was organized as a series of short presentations covering scientific (gene‐gene and gene‐environment interaction, complex phenotypes, and rare variants and next generation sequencing) and methodological (simulation modeling and computational resources and data management) topic areas. Specific needs to advance the field were identified during each session and are summarized.Genet. Epidemiol. 36 : 22–35, 2012. © 2011 Wiley Periodicals, Inc.
A Genome-Wide Association Study of Overall Survival in Pancreatic Cancer Patients Treated with Gemcitabine in CALGB 80303
Innocenti, Federico , Owzar, Kouros , Cox, Nancy, Evans, Patrick , Kubo, Michiaki , Zembutsu, Hitoshi , Jiang, Chen , Hollis, Donna, Li, Liang , Friedman, Paula N., Wang, Liewei , Glubb, Dylan M. , Hurwitz, Herbert I. , McLeod, Howard L. , Goldberg, Richard M. , Schilsky, Richard L. , Kindler, Hedy L. , Nakamura, Yusuke , Ratain, Mark J. , Cox, Nancy J. , Mushiroda, Taisei , Giacomini, Kathleen M. , Li, Liang

Mayo Clinic

Clinical Cancer Research | December 6, 2011 | Volume: 18 | Issue: 2 | Pages: 577-584

10.1158/1078-0432.ccr-11-1387 | PMID 22142827 Get It

Abstract Background and Aims: Cancer and Leukemia Group B 80303 was a randomized, phase III study in patients with advanced pancreatic cancer treated with gemcitabine plus either bevacizumab or placebo. We prospectively collected germline DNA and conducted a genome-wide association study (GWAS) using overall survival (OS) as the endpoint. Experimental Design: DNA from 351 patients was genotyped for more than 550,000 single-nucleotide polymorphisms (SNP). Associations between OS and SNPs were investigated using the log-linear 2-way multiplicative Cox proportional hazards model. The subset of 294 genetically European patients was used for the primary analysis. Results: A nonsynonymous SNP in interleukin (IL)17F (rs763780, H161R) and an intronic SNP in strong linkage disequilibrium (rs7771466) were associated with OS using genome-wide criteria (P ≤ 10−7). Median OS was significantly shorter (P = 2.61 × 10−8) for the rs763780 heterozygotes [3.1 months; 95% confidence interval (CI), 2.3–4.3] than for the patients without this variant (6.8 months; 95% CI, 5.8–7.3). After adjustment by stratification factors, the P value for the association was 9.51 × 10−7. Conclusions: The variant 161R form of IL-17F is a natural antagonist of the antiangiogenic effects of wild-type 161H IL-17F, and angiogenesis may play an important role in the metastatic spread of pancreatic cancer. In this preliminary study, we hypothesize that the angiogenetic potential of pancreatic cancers in patients with variant IL-17F is higher than that of tumors in patients with wild-type IL-17F, conferring worse prognosis. This exploratory GWAS may provide the foundation for testing the biology and clinical effects of novel genes and their heritable variants through mechanistic and confirmatory studies in pancreatic cancer. Clin Cancer Res; 18(2); 577–84. ©2011 AACR.
BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Melanoma
Kim, Kevin B. , Sosman, Jeffrey A. , Fruehauf, John P. , Linette, Gerald P. , Nguyen, Hoa , Cheverton, Peter, Chen, Daniel S. , Peterson, Amy , Carson, William E. , Markovic, Svetomir N. , McDermott, David F. , Weber, Jeffrey S. , Peterson, Amy , O'Day, Steven J , Carson, William E

Mayo Clinic

Journal of Clinical Oncology | November 29, 2011 | Volume: 30 | Issue: 1 | Pages: 34-41

10.1200/jco.2011.34.6270 | PMID 22124101 Get It

Purpose Metastatic melanoma, a highly vascularized tumor with strong expression of vascular endothelial growth factor, has an overall poor prognosis. We conducted a placebo-controlled, double-blind phase II study of carboplatin plus paclitaxel with or without bevacizumab in patients with previously untreated metastatic melanoma. Patients and Methods Patients were randomly assigned in a two-to-one ratio to carboplatin (area under the curve, 5) plus paclitaxel (175 mg/m 2 ) and bevacizumab (15 mg/kg; CPB) or placebo (CP) administered intravenously once every 3 weeks. Progression-free survival (PFS) was the primary end point. Secondary end points included overall survival (OS) and safety. Results Two hundred fourteen patients (73% with M1c disease) were randomly assigned. With a median follow-up of 13 months, median PFS was 4.2 months for the CP arm (n = 71) and 5.6 months for the CPB arm (n = 143; hazard ratio [HR], 0.78; P = .1414). Overall response rates were 16.4% and 25.5%, respectively (P = .1577). With 13-month follow-up, median OS was 8.6 months in the CP arm versus 12.3 months in the CPB arm (HR, 0.67; P = .0366), whereas in an evaluation 4 months later, it was 9.2 versus 12.3 months, respectively (HR, 0.79; P = .1916). In patients with elevated serum lactate dehydrogenase (n = 84), median PFS and OS were longer in the CPB arm (PFS: 4.4 v 2.7 months; HR, 0.62; OS: 8.5 v 7.5 months; HR, 0.52). No new safety signals were observed. Conclusion The study did not meet the primary objective of statistically significant improvement in PFS with the addition of bevacizumab to carboplatin plus paclitaxel. A larger phase III study will be necessary to determine whether there is benefit to the addition of bevacizumab to carboplatin plus paclitaxel in this disease setting.
GH Does Not Modulate the Early Fasting-Induced Release of Free Fatty Acids in Mice
Steyn, Frederik J. , Leong, J. W., Huang, Lili , Tan, H. Y. , Xie, T. Y. , NELSON, CARL, Waters, Michael J. , Veldhuis, Johannes D. , Epelbaum, Jacques, Chen, Chen , Steyn, F J , Chen, C

Mayo Clinic

Endocrinology | November 23, 2011 | Volume: 153 | Issue: 1 | Pages: 273-282

10.1210/en.2011-1681 | PMID 22109889 Get It

Fasting results in the mobilization of adipose stores and the elevation of levels of free fatty acids (FFA). In humans, this process is driven by a release in GH. Little is known regarding the role of GH in modulating this process during early stages of fasting in the mouse. Confirmation of the role of GH in modulating FFA release in the fasting mouse is of particular importance given the frequent use of mouse models to study metabolic mechanisms. Here, we correlate the initial release of FFA throughout fasting in mice with pulsatile GH secretion. Observations illustrate the rapid release of FFA in response to food withdrawal. This does not correlate with a rise in GH secretion. Rather, we observed a striking loss in pulsatile secretion of GH throughout the first 6 h of fasting, suggesting that GH does not modulate the initial release of FFA in the mouse in response to fasting. This was confirmed in GH receptor knockout mice, in which we observed a robust fasting-induced rise in FFA. We further illustrate the dynamic relationship between the orexigenic and anorexigenic hormones ghrelin and leptin during fasting in the mouse. Our findings show an initial suppression of leptin and the eventual rise in circulating levels of acyl-ghrelin with fasting. However, altered acyl-ghrelin and leptin secretion occurs well after the rise in FFA and the suppression of GH secretion. Consequently, we conclude that although acyl-ghrelin and leptin may modulate the physiological response to drive food intake, these changes do not contribute to the initial loss of pulsatile GH secretion. Rather, it appears that the suppression of GH secretion in fasting may occur in response to an elevation in fasting levels of FFA or physiological stress. Observations highlight a divergent role for GH in modulating FFA release between man and mouse.
Experimental mild renal insufficiency mediates early cardiac apoptosis, fibrosis, and diastolic dysfunction: a kidney-heart connection
Martín, Fernando L., Cataliotti, Alessandro , Sangaralingham, S. Jeson , Kořínek, Josef , Huntley, Brenda K., Oehler, Elise A., Harders, Gerald E., Ichiki, Tomoko , Mangiafico, Sarah, Nath, Karl A. , Redfield, Margaret M. , Chen, Horng H. , Burnett, John C. , McKie, Paul M. , Sangaralingham, S. Jeson

Mayo Clinic

American Journal of Physiology-Regulatory, Integrative and Comparative Physiology | November 10, 2011 | Volume: 302 | Issue: 2 | Pages: R292-R299

10.1152/ajpregu.00194.2011 | PMID 22071162 Get It

Impaired renal function with loss of nephron number in chronic renal disease (CKD) is associated with increased cardiovascular morbidity and mortality. However, the structural and functional cardiac response to early and mild reduction in renal mass is poorly defined. We hypothesized that mild renal impairment produced by unilateral nephrectomy (UNX) would result in early cardiac fibrosis and impaired diastolic function, which would progress to a more global left ventricular (LV) dysfunction. Cardiorenal function and structure were assessed in rats at 4 and 16 wk following UNX or sham operation (Sham); ( n = 10 per group). At 4 wk, blood pressure (BP), aldosterone, glomerular filtration rate (GFR), proteinuria, and plasma B-type natriuretic peptide (BNP) were not altered by UNX, representing a model of mild early CKD. However, UNX was associated with significantly greater LV myocardial fibrosis compared with Sham. Importantly, terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) staining revealed increased apoptosis in the LV myocardium. Further, diastolic dysfunction, assessed by strain echocardiography, but with preserved LVEF, was observed. Changes in genes related to the TGF-β and apoptosis pathways in the LV myocardium were also observed. At 16 wk post-UNX, we observed persistent LV fibrosis and impairment in LV diastolic function. In addition, LV mass significantly increased, as did LVEDd, while there was a reduction in LVEF. Aldosterone, BNP, and proteinuria were increased, while GFR was decreased. The myocardial, structural, and functional alterations were associated with persistent changes in the TGF-β pathway and even more widespread changes in the LV apoptotic pathway. These studies demonstrate that mild renal insufficiency in the rat results in early cardiac fibrosis and impaired diastolic function, which progresses to more global LV remodeling and dysfunction. Thus, these studies importantly advance the concept of a kidney-heart connection in the control of myocardial structure and function.
Diabetic Mastopathy as a Radiographically Occult Palpable Breast Mass
Thanarajasingam, Uma , Chen, Beiyun, Tortorelli, Cindy L., Jakub, James W. , Ghosh, Karthik, Jakub, James W

Mayo Clinic

Case Reports in Medicine | November 3, 2011 | Volume: 2011 | Issue: No issue available | Pages: 1-3

10.1155/2011/162350 | PMID 22110508 Get It

Diabetic mastopathy is an uncommon, benign disease of the breast that can occur in women with diabetes and clinically mimic breast cancer. We describe a patient with long-standing type 1 diabetes who presented with a palpable breast mass with negative imaging findings on mammography, ultrasonography, and breast MRI. Surgical biopsy and histopathology confirmed diabetic mastopathy. We use this case to highlight the recognition, radiographic features, pathology, and management of this benign breast condition and emphasize that, in diabetic patients, the differential diagnosis of a new breast mass should include diabetic mastopathy.
Sequential Versus Concurrent Trastuzumab in Adjuvant Chemotherapy for Breast Cancer
Perez, Edith A. , Davidson, Nancy E. , Visscher, Daniel W., Chen, Beiyun, Dakhil, Shaker R. , Zujewski, JoAnne, Moreno‐Aspitia, Alvaro , Pisansky, Thomas M. , Jenkins, Robert B. , Suman, Vera J. , Gralow, Julie R. , Kaufman, Peter A. , Ingle, James N.

Mayo Clinic

Journal of Clinical Oncology | November 1, 2011 | Volume: 29 | Issue: 34 | Pages: 4491-4497

10.1200/jco.2011.36.7045 | PMID 22042958 Get It

Purpose NCCTG (North Central Cancer Treatment Group) N9831 is the only randomized phase III trial evaluating trastuzumab added sequentially or used concurrently with chemotherapy in resected stages I to III invasive human epidermal growth factor receptor 2–positive breast cancer. Patients and Methods Patients received doxorubicin and cyclophosphamide every 3 weeks for four cycles, followed by paclitaxel weekly for 12 weeks (arm A), paclitaxel plus sequential trastuzumab weekly for 52 weeks (arm B), or paclitaxel plus concurrent trastuzumab for 12 weeks followed by trastuzumab for 40 weeks (arm C). The primary end point was disease-free survival (DFS). Results Comparison of arm A (n = 1,087) and arm B (n = 1,097), with 6-year median follow-up and 390 events, revealed 5-year DFS rates of 71.8% and 80.1%, respectively. DFS was significantly increased with trastuzumab added sequentially to paclitaxel (log-rank P < .001; arm B/arm A hazard ratio [HR], 0.69; 95% CI, 0.57 to 0.85). Comparison of arm B (n = 954) and arm C (n = 949), with 6-year median follow-up and 313 events, revealed 5-year DFS rates of 80.1% and 84.4%, respectively. There was an increase in DFS with concurrent trastuzumab and paclitaxel relative to sequential administration (arm C/arm B HR, 0.77; 99.9% CI, 0.53 to 1.11), but the P value (.02) did not cross the prespecified O'Brien-Fleming boundary (.00116) for the interim analysis. Conclusion DFS was significantly improved with 52 weeks of trastuzumab added to adjuvant chemotherapy. On the basis of a positive risk-benefit ratio, we recommend that trastuzumab be incorporated into a concurrent regimen with taxane chemotherapy as an important standard-of-care treatment alternative to a sequential regimen.
Investigating Perioperative Heart Migration during Robot-Assisted Coronary Artery Bypass Grafting Interventions
Linte, Cristian A. , Cho, Daniel S., Wedlake, Chris, Moore, John , Chen, Elvis C. S. , Bainbridge, Daniel , Patel, Rajni V. , Peters, Terry M. , Kiaii, Bob

Mayo Clinic

Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery | October 28, 2011 | Volume: 6 | Issue: 5 | Pages: 323-330

10.1097/imi.0b013e3182374e7e | PMID 22436709 Get It

Objective For robot-assisted coronary artery bypass graft interventions, surgeons typically use a preoperative thoracic computed tomography scan of the patient to plan the procedure. However, the cardiac anatomy is prone to changes induced perioperatively in the effort to access the heart and surgical targets, which, in turn, may invalidate the initial plan. This article presents a method to estimate the perioperative heart migration, information which can be further exploited to refine the preoperative surgical plan. Methods Tracked transesophageal ultrasound images of four patients’ hearts were acquired at each stage in the procedure: before lung deflation, after lung deflation, and after both lung deflation and CO 2 thoracic insufflation. Anatomic features of interest—the mitral and aortic valves—were identified from each dataset, and their movement between the different procedure stages was recorded and used to estimate the global heart displacement. Moreover, the local morphology of the features of interest was investigated to provide insight on the extent of the deformation the heart has undergone during the workflow. Results The study suggested that the heart does undergo substantial displacement—on the order of 10 to 15 mm in each direction (axial, coronal, and sagittal) after lung deflation and CO 2 thoracic insufflation. However, no significant differences (P > 0.1) were observed in the morphologic characteristics of the features of interest across the multiple workflow stages, suggesting that local deformations occur at a much smaller scale compared with the global migration. Conclusions The quantification of the perioperatively induced changes is critical to track the displacement of the heart and surgical targets. The recorded migration patterns should not be ignored but rather be used to update the surgical plan to better suit the intraoperative environment.